Q2 FY2026 · ended Jun 30, 2026 · Revenue $25,208, +30.5% YoY · Filed Aug 6, 2026
Aclarion, Inc. (ACON) files with the SEC under industry code 8071, Services-Medical Laboratories. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $25,208 and a net loss of $2.7 million. Free cash flow was -$2.7 million.
Revenue
$25,208
+30.5% vs year-ago quarter
Net income
$-2.75M
-71.6% vs year-ago quarter
Operating cash flow
$-2.66M
-42.4% vs year-ago quarter
Free cash flow
$-2.66M
-42.5% vs year-ago quarter
EPS
$-1.12
+59.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.88M
+394.9% vs year-ago quarter
Net cash
—
Operating margin
-11592.1%
TTM
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- ACON (Nasdaq), ACONW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Broomfield, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1635077
- Former names
- Nocimed, Inc. (until Oct 26, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $25,208 | $21,140 | $18,479 | $18,942 | $19,319 |
| Operating income | -$2.9M | -$3.0M | -$2.0M | -$1.8M | -$1.7M |
| Net income | -$2.7M | -$2.9M | -$1.9M | -$1.7M | -$1.6M |
| Diluted EPS | -$1.12 | -$1.34 | -$2.55 | -$2.93 | -$2.75 |
| Operating cash flow | -$2.7M | -$2.6M | -$1.6M | -$1.2M | -$1.9M |
| Free cash flow | -$2.7M | — | -$1.6M | -$1.2M | -$1.9M |
| Total assets | $18.0M | $20.6M | $13.7M | $13.2M | $14.8M |
| Total liabilities | $1.0M | $986,208 | $837,287 | $699,747 | $564,422 |
| Stockholders' equity | $17.0M | $19.7M | $12.8M | $12.5M | $14.2M |
| Cash and investments | $16.3M | $19.0M | $12.0M | $11.3M | $12.8M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 22, 2026 | Apr 21, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Other events
|
Mar 19, 2026 | Mar 19, 2026 |
All 276 Aclarion, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.